Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Spanish reimbursement system

- PMLiVE

Porterhouse Medical promotes Amanda Lyons

She becomes the agency’s senior account director

Dr Martin Rothman joins Sofinnova Partners

He becomes the firm’s venture partner

The NHS and ABPI at 70: inching closer to the triple win

The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...

Health Unlimited welcomes Ann Bartling in significant new PR hire

Monday 21 May, London: Global health consultancy and communications agency Health Unlimited has added to its senior talent in London with the hire of Ann Bartling as PR Practice Lead....

Health Unlimited

- PMLiVE

More encouraging data for Spark and Pfizer’s potential haemophilia B cure

Pfizer set to commence phase III trials

- PMLiVE

Positive mid-stage trial gives Allergy’s investors some welcome relief

Its grass pollen vaccine showed a “highly significant” dose response

Getting the sizing right

Merger and Acquisition activity in our sector can learn from the natural world

- PMLiVE

Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

Latest data could unlock a new patient population for the Swiss pharma giant’s injection

AstraZeneca AZ

AZ gets US approval for Veltassa rival Lokelma

But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia

- PMLiVE

Data visualisation in medical communications

In the increasingly data-rich but time-poor environment of front-line healthcare providers, doctors face the challenge of maintaining up-to-date clinical knowledge. Given that it is estimated that by 2020 medical knowledge...

- PMLiVE

Better times ahead, promises AZ as Crestor drop outweighs new drugs

Patent expiry fading says Soriot, as oncology prospects look good

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links